Lupin Teams up with Laboratorios ERN to launch Luforbec®️ PMDI in the Spanish Market
Lupin Limited (Lupin) the Mumbai based Indian pharma major on 08th June announced its strategic collaboration with LABORATORIOS ERN S.A. (ERN), a renowned Spanish pharmaceutical company, for the launch of Luforbec® (beclometasone/formoterol) 100/6, a fixed...
Novartis Strengthens Autoimmune Disease Portfolio with Key Highlights from EULAR 2026
Novartis AG concluded a defining presence at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress today at ExCeL London, presenting pivotal findings from 31...
AstraZeneca’s Ultomiris®️ Cuts Proteinuria by 43.4% in Phase – 3 Trial
Alexion, AstraZeneca Rare Disease, announced positive results from a prespecified interim analysis of the global Phase III I CAN trial. The data demonstrate...
Lupin Gets U.S. FDA Approval for Ranluspec™ to Treat Retinal Disorders
Lupin Limited has secured U.S. FDA approval for Ranluspec™ (ranibizumab-hkdz), an interchangeable biosimilar to Genentech’s Lucentis® — a milestone that reshapes patient access to sight-saving biologics across...
Glenmark Launches Generic Vimpat®️ Injection in the US to Expand Injectable Portfolio
Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the official launch of its Lacosamide Injection USP, 200mg/mL,20mg/mL, 10mg/mL available in Single-Dose Vials, as detailed in the official...
Telangana & South Africa Forge Strategic Alliance in Pharma, Medical Tourism, and ‘Bharat Future City
Telangana Chief Minister A Revanth Reddy hosted a high-level bilateral meeting with a South African delegation led by Deputy President Paul Mashatile to expand...